|
India News Releases
|
(India.CityRegions.Com, May 14, 2016 ) The report provides comprehensive information on the therapeutics under development for Sanofi, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sanofi and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Other Key Points in Report:
- The report provides a snapshot of the global therapeutic landscape of Sanofi - The report reviews pipeline therapeutics for Sanofi by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Sanofi therapeutics and enlists all their major and minor projects - The report assesses Sanofi therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
Inquire before Purchasing Report @ http://www.reportsweb.com/inquiry&RW0001236092/buying
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sanofi - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sanofi pipeline depth and focus of Indication therapeutics
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001236092/sample
Table of Content: An Overview
Sanofi Snapshot 6 Sanofi Overview 6 Key Information 6 Key Facts 6 Sanofi - Research and Development Overview 7 Key Therapeutic Areas 7 Sanofi - Pipeline Review 13 Pipeline Products by Stage of Development 13 Pipeline Products - Monotherapy 14 Pipeline Products - Combination Treatment Modalities 15 Pipeline Products - Partnered Products 16 Pipeline Products - Out-Licensed Products 19 Sanofi - Pipeline Products Glance 21 Sanofi - Late Stage Pipeline Products 21 Sanofi - Clinical Stage Pipeline Products 24 Sanofi - Early Stage Pipeline Products 26 Sanofi - Drug Profiles 28 (insulin glargine + lixisenatide) 28 lixisenatide 31
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001236092/discount
mipomersen sodium 35 semuloparin sodium 37 (fexofenadine hydrochloride + phenylephrine hydrochloride) 38 avanafil 39 cabazitaxel 40 insulin lispro 42 ziv-aflibercept (recombinant) 43 fexinidazole 47 (capecitabine + cyclophosphamide) 49 alemtuzumab 50 artefenomel + ferroquine 53 ataciguat 55 efpeglenatide 56 isatuximab 58 plerixafor 60 SAR-156597 63 sotagliflozin 64 pilaralisib 66 SAR-408701 69 SAR-421869 70 SAR-422459 72 voxtalisib 74 Monoclonal Antibodies to Inhibit Abeta for Alzheimer's Disease 76 SAR-113244 77 SAR-228810 78
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001236092/buy/1500
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us: Email: sales@reportsweb.com Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|
|
|
India RSS Feed Marketpalce
|
India News Headlines
Daily news from India: arts, business, culture, politics, science, technology & more.
Free Sales & Marketing Magazines
Get free publications about marketing, sales and customer relations management.
Submit RSS feed on India. Have your feed on news, products or services displayed under this marketpalce and have your feed on a full page updated daily.
|
|
India Business News by Major Cities
|
|
|
Listen to GroupWeb Radio
INDIA BUSINESS TV
|